SUBSCRIBE
SUBSCRIBE
News   Business

Biosyntech Inc. Signs Agreement With MedQualis As BST-DermOn’TM’ And BST-InPod’TM’ Clinical Trial CRO

October 19, 2005 | 
1 min read

BIOSYNTECH (TSX Venture:BSY) is pleased to announce the appointment of MedQualis, a contract research organization (CRO) to support BioSyntech in their upcoming BST-DermOn(TM) and BST-InPod(TM) Canadian clinical trials.

Alliances
MORE ON THIS TOPIC
A human hand showing dollar golden coins in the jar with a colored background. Collage Art of finance
Manufacturing
J&J, Legend Pump $150M Into Manufacturing in Bid to Double Carvykti Production
March 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of two arrows merging into one
Mergers & acquisitions
Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
March 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Merck building and sign in Silicon Valley
Vaccines
Good Day for Gardasil as Merck Wins Safety Suit, Drops $1B for Manufacturing Push
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Concept of money prize. Vector illustration. Halftone hand holds bouquet of money flowers. Gift prize, donation, earnings, bonus or cashback concept. Retro poster or banner. Creative trend collage.
Weight loss
Roche Makes Another Obesity Play With Potential $5.3B Amylin Pact With Zealand
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac